Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT – Free Report) – Lifesci Capital issued their FY2023 earnings estimates for Rocket Pharmaceuticals in a research report issued to clients and investors on Tuesday, December 26th. Lifesci Capital analyst C. Jubinville expects that the biotechnology company will earn ($2.97) per share for the year. Lifesci Capital has a “Outperform” rating […]
VYNE Therapeutics (NASDAQ:VYNE – Get Free Report) and Rocket Pharmaceuticals (NASDAQ:RCKT – Get Free Report) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, dividends, risk, profitability, analyst recommendations and institutional ownership. Valuation and Earnings This table compares VYNE Therapeutics […]
The biotech stock with the BofA's biggest upside already has approval for a drug that treats a rare kidney disease affecting up to 150,000 people in the U.S.